Aligos Therapeutics, Inc. (ALGS) Misses Q3 EPS by 290c
Tweet
Share
E-mailGet Alerts ALGS Hot Sheet
Join SI Premium – FREE
Aligos Therapeutics, Inc. (NASDAQ: ALGS) reported Q3 EPS of ($3.07), $2.90 worse than the analyst estimate of ($0.17).
For earnings history and earnings-related data on Aligos Therapeutics, Inc. (ALGS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Reading (RDI) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
